PMPeter E. Morris

Peter E. Morris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter E. Morris has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Early ICU Standardized Rehabilitation Therapy for the Critically Injured Burn Patient

    by Peter E. Morris, James Holmes, Brad Freeman, Bruce Cairns, Michael Berry, L. D. Case

    This is a multicenter, randomized controlled trial to determine whether early ICU rehabilitation, for Burn Intensive Care Unit (BICU) patients will decrease hospital length of stay. 50 subjects will be randomized at each of three sites for a total of 150 subjects, The study has completed all regulatory requirements, completed site protocol developments and has begun to enroll patients, The goal enrollment minimums are an average of 2.5 patients enrolled per month, per site; 7.5 patients enrolled per month, across the study. This study will increase understanding of the effect of rehabilitation on ICU Burn patients, through ultrasound and strength assessments of muscles, performed at study entry (ultrasound), ICU & Hospital discharge and at 3, 6 and 12 months (ultrasound & strength assessments) post-enrollment. Functional testing with Short Physical Performance Battery (SPPB) and Health Related Quality of Life (HRQoL) testing will determine if standardized early rehab improves functional performance, quality of life and employment status. Accomplishments Year #1: Database build, design web entry case report forms, site training; finalized IRB consent forms and began enrollment, 3 subjects to date, with outpatient follow-up 3, 6, and 12 month sessions planned. Accomplishments Year #2; Active Study with enrollment of study subjects at all three sites. Completion of training of ultrasound techniques at all three sites. Out-patient follow-up has begun for those enrolled within the first year of the study.

  • Open Access

    A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock

    by Peter E Morris, Brian Zeno, Andrew C Bernard, Xiangning Huang, Shampa Das, Timi Edeki, Steven G Simonson, Gordon R Bernard

    Introduction: Tumor necrosis factor-alpha (TNF-α), an early mediator in the systemic inflammatory response to infection, is a potential therapeutic target in sepsis. The primary objective of this study was to determine the safety and tolerability of AZD9773, an ovine, polyclonal, anti-human TNF-α Fab preparation, in patients with severe sepsis. Secondary outcomes related to pharmacokinetic (PK) and pharmacodynamic (PD) parameters. Methods: In this double-blind, placebo-controlled, multicenter Phase IIa study, patients were sequentially enrolled into five escalating-dose cohorts (single doses of 50 or 250 units/kg; multiple doses of 250 units/kg loading and 50 units/kg maintenance, 500 units/kg loading and 100 units/kg maintenance, or 750 units/kg loading and 250 units/kg maintenance). In each cohort, patients were randomized 2:1 to receive AZD9773 or placebo. Results: Seventy patients received AZD9773 (n = 47) or placebo (n = 23). Baseline characteristics were similar across cohorts. Mean baseline APACHE score was 25.9. PK data demonstrated an approximately proportional increase in concentration with increasing dose and a terminal half-life of 20 hours. For the multiple-dose cohorts, serum TNF-α concentrations decreased to near-undetectable levels within two hours of commencing AZD9773 infusion. This suppression was maintained in most patients for the duration of treatment. AZD9773 was well tolerated. Most adverse events were of mild-to-moderate intensity and considered by the reporting investigator as unrelated to study treatment. Conclusions: The safety, PK and PD data support the continued evaluation of AZD9773 in larger Phase IIb/III studies.


  • Open Access

    A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome

    by Peter E Morris, Jay S Steingrub, Bee Y Huang, Shamay Tang, Patrick M Liu, Peter R Rhode, Hing C Wong

    Background: The tissue factor (TF)-dependent extrinsic pathway has been suggested to be a central mechanism by which the coagulation cascade is locally activated in the lungs of patients with acute lung injury and acute respiratory distress syndrome (ALI/ARDS) and thus represents an attractive target for therapeutic intervention. This study was designed to determine the pharmacokinetic and safety profiles of ALT-836, an anti-TF antibody, in patients with ALI/ARDS. Methods: This was a prospective, randomized, placebo-controlled, dose-escalation Phase I clinical trial in adult patients who had suspected or proven infection, were receiving mechanical ventilation and had ALI/ARDS (PaO2/FiO2 ≤ 300 mm). Eighteen patients (6 per cohort) were randomized in a 5:1 ratio to receive ALT-836 or placebo, and were treated within 48 hours after meeting screening criteria. Cohorts of patients were administered a single intravenously dose of 0.06, 0.08 or 0.1 mg/kg ALT-836 or placebo. Blood samples were taken for pharmacokinetic and immunogenicity measurements. Safety was assessed by adverse events, vital signs, ECGs, laboratory, coagulation and pulmonary function parameters. Results: Pharmacokinetic analysis showed a dose dependent exposure to ALT-836 across the infusion range of 0.06 to 0.1 mg/kg. No anti-ALT-836 antibody response was observed in the study population during the trial. No major bleeding episodes were reported in the ALT-836 treated patients. The most frequent adverse events were anemia, observed in both placebo and ALT-836 treated patients, and ALT-836 dose dependent, self-resolved hematuria, which suggested 0.08 mg/kg as an acceptable dose level of ALT-836 in this patient population. Conclusions: Overall, this study showed that ALT-836 could be safely administered to patients with sepsis-induced ALI/ARDS. Trial registration: ClinicalTrials.gov: NCT01438853


  • Receiving Early Mobility During an Intensive Care Unit Admission Is a Predictor of Improved Outcomes in Acute Respiratory Failure

    by Peter E. Morris, Leah Griffin, Clif Thompson, R. Duncan Hite, Edward Haponik, Michael Berry, Chris Winkelman, Ramona O. Hopkins, Amelia Ross, Luz Dixon, et al.


  • Open Access

    A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults

    by Peter E Morris, John T Promes, Kalpalatha K Guntupalli, Patrick E Wright, Murray M Arons

    Introduction: Hospitalized patients are often unable to ingest or tolerate oral antipyretics and recently an aqueous formulation of intravenous (IV) ibuprofen was approved by the US-FDA for the reduction of fever in adults. Methods: We evaluated IV ibuprofen to reduce fever exceeding 101.0°F, measured as the percentage of subjects achieving a temperature P = 0.0264; 200 mg IV ibuprofen n = 21/30 (70%) P = 0.0043; 400 mg IV ibuprofen n = 24/31 (77%) P = 0.0005. A total of 53/120 patients (44%) were prospectively defined as critically ill at baseline and similar temperature reductions were observed in this subgroup. There were no statistically significant differences between treatment groups or when compared to placebo in transfusion, bleeding, renal failure or mortality. Conclusions: All doses of IV ibuprofen tested reduced fever at four hours and throughout the first 24 hours of dosing. The 400 mg dose was effective in lowering temperature to normal and maintaining this over the first 24 hours of dosing. IV ibuprofen was effective in reducing fevers in critically ill and non-critically ill groups. Following 24 hours of administration of IV ibuprofen, no clinically significant differences in any safety parameter including renal function or bleeding occurred through the 28-day follow-up period. Trial registrations: Clinicaltrials.gov registration number: NCT01131000.


  • Top Cited Papers

    Early intensive care unit mobility therapy in the treatment of acute respiratory failure*

    by Peter E. Morris, Amanda Goad, Clifton Thompson, Karen Taylor, Bethany Harry, Leah Passmore, Amelia Ross, Laura Anderson, Shirley Baker, Mary Sanchez, et al.

    Immobilization and subsequent weakness are consequences of critical illness. Despite the theoretical advantages of physical therapy to address this problem, it has not been shown that physical therapy initiated in the intensive care unit offers benefit. Prospective cohort study in a university medical intensive care unit that assessed whether a mobility protocol increased the proportion of intensive care unit patients receiving physical therapy vs. usual care. Medical intensive care unit patients with acute respiratory failure requiring mechanical ventilation on admission: Protocol, n = 165; Usual Care, n = 165. An intensive care unit Mobility Team (critical care nurse, nursing assistant, physical therapist) initiated the protocol within 48 hrs of mechanical ventilation. The primary outcome was the proportion of patients receiving physical therapy in patients surviving to hospital discharge. Baseline characteristics were similar between groups. Outcome data are reflective of survivors. More Protocol patients received at least one physical therapy session than did Usual Care (80% vs. 47%, p < or = .001). Protocol patients were out of bed earlier (5 vs. 11 days, p < or = .001), had therapy initiated more frequently in the intensive care unit (91% vs. 13%, p < or = .001), and had similar low complication rates compared with Usual Care. For Protocol patients, intensive care unit length of stay was 5.5 vs. 6.9 days for Usual Care (p = .025); hospital length of stay for Protocol patients was 11.2 vs. 14.5 days for Usual Care (p = .006) (intensive care unit/hospital length of stay adjusted for body mass index, Acute Physiology and Chronic Health Evaluation II, vasopressor). There were no untoward events during an intensive care unit Mobility session and no cost difference (survivors + nonsurvivors) between the two arms, including Mobility Team costs. A Mobility Team using a mobility protocol initiated earlier physical therapy that was feasible, safe, did not increase costs, and was associated with decreased intensive care unit and hospital length of stay in survivors who received physical therapy during intensive care unit treatment compared with patients who received usual care.


  • Early Intensive Care Unit Mobility: Future Directions

    by Peter E. Morris, Margaret S. Herridge


  • Open Access

    The ARDS Support Center

    by Michael J Raggio, Peter E Morris